FGFR2 amplification in gastric/GEJ adenocarcinoma (~5-7% high-level): bemarituzumab (anti...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BMA-FGFR2-AMP-GASTRIC`
Type	Actionability
Status	reviewed 2026-04-27 \| pending_clinical_signoff \| actionability review required
Diseases	`DIS-GASTRIC`
Sources	`SRC-CIVIC` `SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Actionability Facts

Biomarker	`BIO-FGFR2`
Variant	amplification (~5-7% gastric/GEJ; high-level GCN ≥10)
Disease	`DIS-GASTRIC`
ESCAT tier	IIA
Recommended combinations	bemarituzumab + mFOLFOX6 (FGFR2b IHC 2+/3+ ≥10% — investigational, FORTITUDE-101), futibatinib / pemigatinib (off-label / basket trial for FGFR2-amp)
Evidence summary	FGFR2 amplification in gastric/GEJ adenocarcinoma (~5-7% high-level): bemarituzumab (anti-FGFR2b mAb) + mFOLFOX6 improved PFS/OS in FGFR2b-overexpressing 1L gastric (FIGHT phase 2, Wainberg Lancet Oncol 2022 — PFS 9.5 vs 7.4 mo; phase 3 FORTITUDE-101 ongoing). Selective FGFR-TKIs (futibatinib, pemigatinib) have basket activity in FGFR2-amp gastric.

Notes

ESCAT IIA. OncoKB Level 3A. Bemarituzumab uses FGFR2b IHC (not amplification per se) as companion. 1L gastric standard remains fluoropyrimidine + platinum ± trastuzumab (HER2+) ± nivolumab (PD-L1+) until FORTITUDE-101 reads out. Trial-source gap: SRC-FIGHT / SRC-FORTITUDE-101 not yet ingested.

Used By

Actionability

BMA-FGFR2B-MEMBRANE-GASTRIC - FGFR2b protein overexpression (IHC 2+/3+ membranous in ≥10% of tumor cells) identifies a...